Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.

[1]  A. Breckenridge.  Post‐marketing Strategies for Medicines , 2008, Clinical pharmacology and therapeutics.

[2]  S. Schneeweiss,et al.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. , 2007, Journal of clinical epidemiology.

[3]  J. Allison,et al.  Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. , 2007, Arthritis and rheumatism.

[4]  L. Jacobsson,et al.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists , 2007, Annals of the rheumatic diseases.

[5]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[6]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[7]  P. Kerstens,et al.  Infections during low-dose methotrexate treatment in rheumatoid arthritis. , 1995, Seminars in arthritis and rheumatism.

[8]  A. van der Heide,et al.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. , 1994, Annals of the rheumatic diseases.